176 related articles for article (PubMed ID: 27172970)
1. Comparative Cost-Effectiveness of Hypertension Treatment in Non-Hispanic Blacks and Whites According to 2014 Guidelines: A Modeling Study.
Vasudeva E; Moise N; Huang C; Mason A; Penko J; Goldman L; Coxson PG; Bibbins-Domingo K; Moran AE
Am J Hypertens; 2016 Oct; 29(10):1195-205. PubMed ID: 27172970
[TBL] [Abstract][Full Text] [Related]
2. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
Gu D; He J; Coxson PG; Rasmussen PW; Huang C; Thanataveerat A; Tzong KY; Xiong J; Wang M; Zhao D; Goldman L; Moran AE
PLoS Med; 2015 Aug; 12(8):e1001860. PubMed ID: 26241895
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
[TBL] [Abstract][Full Text] [Related]
4. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
Moise N; Huang C; Rodgers A; Kohli-Lynch CN; Tzong KY; Coxson PG; Bibbins-Domingo K; Goldman L; Moran AE
Hypertension; 2016 Jul; 68(1):88-96. PubMed ID: 27181996
[TBL] [Abstract][Full Text] [Related]
5. Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study.
Li C; Chen K; Cornelius V; Tomeny E; Wang Y; Yang X; Yuan X; Qin R; Yu D; Wu Z; Wang D; Chen T
PLoS Med; 2021 Mar; 18(3):e1003515. PubMed ID: 33661907
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Antihypertensive Medication: Exploring Race and Sex Differences Using Data From the REasons for Geographic and Racial Differences in Stroke Study.
Tajeu GS; Mennemeyer S; Menachemi N; Weech-Maldonado R; Kilgore M
Med Care; 2017 Jun; 55(6):552-560. PubMed ID: 28333708
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Initiating Pharmacological Treatment in Stage One Hypertension Based on 10-Year Cardiovascular Disease Risk: A Markov Modeling Study.
Constanti M; Floyd CN; Glover M; Boffa R; Wierzbicki AS; McManus RJ
Hypertension; 2021 Feb; 77(2):682-691. PubMed ID: 33342242
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Hypertension Treatment by Pharmacists in Black Barbershops.
Bryant KB; Moran AE; Kazi DS; Zhang Y; Penko J; Ruiz-Negrón N; Coxson P; Blyler CA; Lynch K; Cohen LP; Tajeu GS; Fontil V; Moy NB; Ebinger JE; Rader F; Bibbins-Domingo K; Bellows BK
Circulation; 2021 Jun; 143(24):2384-2394. PubMed ID: 33855861
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients.
Lubitz CC; Economopoulos KP; Sy S; Johanson C; Kunzel HE; Reincke M; Gazelle GS; Weinstein MC; Gaziano TA
Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):621-30. PubMed ID: 26555126
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Drug Treatment for Chinese Patients With Stage I Hypertension According to the 2017 Hypertension Clinical Practice Guidelines.
Zhou YF; Liu N; Wang P; Jeong Yang J; Song XY; Pan XF; Zhang X; He M; Li H; Gao YT; Xiang YB; Wu T; Yu D; Pan A
Hypertension; 2020 Sep; 76(3):750-758. PubMed ID: 32713271
[TBL] [Abstract][Full Text] [Related]
11. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
12. Telemonitoring and self-management in the control of hypertension (TASMINH2): a cost-effectiveness analysis.
Kaambwa B; Bryan S; Jowett S; Mant J; Bray EP; Hobbs FD; Holder R; Jones MI; Little P; Williams B; McManus RJ
Eur J Prev Cardiol; 2014 Dec; 21(12):1517-30. PubMed ID: 23990660
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
Ferket BS; Hunink MG; Khanji M; Agarwal I; Fleischmann KE; Petersen SE
Heart; 2017 Apr; 103(7):483-491. PubMed ID: 28077465
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Masked Hypertension Screening and Treatment in US Adults With Suspected Masked Hypertension: A Simulation Study.
Green MB; Shimbo D; Schwartz JE; Bress AP; King JB; Muntner P; Sheppard JP; McManus RJ; Kohli-Lynch CN; Zhang Y; Shea S; Moran AE; Bellows BK
Am J Hypertens; 2022 Aug; 35(8):752-762. PubMed ID: 35665802
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Intensive vs Standard Blood Pressure Control Among Older Patients With Hypertension.
Liao CT; Toh HS; Sun L; Yang CT; Hu A; Wei D; Melgarejo J; Zhang ZY
JAMA Netw Open; 2023 Feb; 6(2):e230708. PubMed ID: 36848091
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of renin-guided treatment of hypertension.
Smith SM; Campbell JD
Am J Hypertens; 2013 Nov; 26(11):1303-10. PubMed ID: 24048147
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of self-management of blood pressure in hypertensive patients over 70 years with suboptimal control and established cardiovascular disease or additional cardiovascular risk diseases (TASMIN-SR).
Penaloza-Ramos MC; Jowett S; Mant J; Schwartz C; Bray EP; Sayeed Haque M; Richard Hobbs FD; Little P; Bryan S; Williams B; McManus RJ
Eur J Prev Cardiol; 2016 Jun; 23(9):902-12. PubMed ID: 26603745
[TBL] [Abstract][Full Text] [Related]
18. Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance?
Mar J; Rodríguez-Artalejo F
J Hypertens; 2001 Jan; 19(1):149-55. PubMed ID: 11204296
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands.
Stevanović J; O'Prinsen AC; Verheggen BG; Schuiling-Veninga N; Postma MJ; Pechlivanoglou P
Clin Ther; 2014 Mar; 36(3):368-84.e5. PubMed ID: 24534654
[TBL] [Abstract][Full Text] [Related]
20. A Round-Up on Cost-Effectiveness of Hypertension Therapy Based on the 2014 Guidelines.
Wani P; Blanco-Garcia C
Curr Cardiol Rep; 2016 Mar; 18(3):24. PubMed ID: 26841786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
